Logo-ijhpm
Int J Health Policy Manag. 2022;11(9): 1735-1743. doi: 10.34172/ijhpm.2021.75
PMID: 34380200        PMCID: PMC9808230

Original Article

Unbalanced Treatment Costs of Breast Cancer in China: Implications From the Direct Costs of Inpatient and Outpatient Care in Liaoning Province

Zihua Ma 1 ORCID, Gongman Deng 2, Zhaolin Meng 3, Yanan Ma 4 * ORCID, Huazhang Wu 1 * ORCID

Cited by CrossRef:

1- Wei Q, Xu Y, Liu W, Guan X. Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China. Cost Eff Resour Alloc. 2023;21(1) [Crossref]
2- Afaya A, Ramazanu S, Bolarinwa O, Yakong V, Afaya R, Aboagye R, Daniels-Donkor S, Yahaya A, Shin J, Dzomeku V, Ayanore M, Alhassan R. Health system barriers influencing timely breast cancer diagnosis and treatment among women in low and middle-income Asian countries: evidence from a mixed-methods systematic review. BMC Health Serv Res. 2022;22(1) [Crossref]